Such was the influence of the Triple Alliance (the British Veterinary Association, the Committee for the Reform of Animal Experimentation and FRAME), when the Animals (Scientific Procedures) Bill 1985 was being drafted and considered by Parliament, we were able to insist on the inclusion of Section 5 (4) , which states that, "In determining whether and on what terms to grant a project licence, the Secretary of State shall weigh the likely adverse effects on the animals concerned against the benefit likely to accrue as a result of the programme to be specified in the licence". 1 I must admit that, while our intentions were clear to all concerned, we had not considered, in any depth, how the Home Secretary, with the support of his officials, would actually assess likely benefit and likely adverse effects, then conduct the weighing of the balance between them.
As a result, since the Animals (Scientific Procedures) Act 1986 came into force, the Home Office has developed its own systems for carrying out this task, and has issued Guidance to assist project licence applicants, 2 in which it is emphasised that, "In practice, this assessment requires more than establishing that the benefit is likely to exceed the welfare costs. The 'benefits' must be maximised. The 'costs', in terms of animal use and suffering, must be minimised."
Costs are considered to be "the adverse welfare effects (pain, suffering, distress or lasting harm) likely to be experienced by the protected animals used during the course of the study". These effects "may be produced by acts of commission or omission; they may be immediate or delayed; and they may be a specific consequence of the procedures or the result of, for example, the care and husbandry systems". 2 The Guidance goes on to say that, "Qualitative (but repeatable and professional) judgements must be made of the likely benefits, the likely severity, and the balance between them. The full balance of likely benefit and likely cost cannot be performed adequately by mathematical calculations." It is also stated that, "Although the Act only requires that the Secretary of State weighs the costs and benefits before granting project licence authorities, the cost/benefit assessment is not a single event exercised only at the beginning of a programme of work. It is a continuous process throughout the life of the licence. Every effort must be made to maximise benefit and minimise severity when work is being planned and whilst work is in progress. The emerging and actual costs and benefits must be evaluated and reviewed, to ensure that the original assumptions and assessment remain sound. Efforts must be made to refine existing protocols wherever possible."
That is all very well, but how effectively do these good intentions work in practice?
The LASA/APC Working Group
There has long been concern in the animal welfare movement about how the costs to laboratory animals are assessed and categorised, and this has been reflected in a number of reports, including those of a House of Lords Select Committee, 3 the Animal Procedures Committee (APC), 4 the Boyd Group, 5 and the Nuffield Council on Bioethics. 6 One point of common agreement was on the need to consider the feasibility of producing data on the actual severity of the scientific procedures performed on the animals during a project, rather than focusing only on the likely adverse effects, as foreseen before the experimental work had begun.
In 2005, in response to these pressures, a Working Group (WG) was convened under the auspices of the Laboratory Animal Science Association (LASA) and the APC, to consider the feasibility of collecting and reporting data on the actual severity of the adverse effects suffered. On the whole, the Final Report of the WG, published in October 2008, 7 is both positive and encouraging. The main conclusions of the WG can be summarised as follows:
1. The introduction of a process for the retrospective reporting of the severity of scientific procedures on animals would be beneficial in terms of enhanced openness and public accountability, and could also bring animal welfare and scientific benefits.
2. Taking into account the pros and cons of a range of different options for reporting, it is recommended that severity be recorded and reported by using a single code for each animal -mild, moderate or substantial -to indicate the maximum actual severity of adverse effects experienced.
At present, data published in the annual Home Office Statistics of Scientific Procedures on
Living Animals are collected when procedures are started. However, severity data have to be collected when procedures have finished. To avoid having to collect and return data at both the beginning and end of procedures, and to enable cross-referencing of severity data with other information in the Statistics, it is recommended that all the statistical data required in the annual returns be collected when procedures have finished.
4. Any change in the method of reporting animal procedures will require a transition period, to ensure that there is no under-counting or overcounting of procedures, that burdens on licensees reporting data are minimised through adequate training, and that there is preservation of historical trends information.
5. Any scheme for retrospective reporting of severity must be supported by detailed guidance, including a catalogue of worked examples covering the full range of species and a wide variety of regulated procedures and outcomes.
The WG's report will be independently reviewed in a future issue of ATLA. Meanwhile, I would like to raise two concerns. Firstly, the members of the WG were all from institutions where laboratory animal procedures are conducted, with no independent advocates of the interests of the animals used by them and by others. No doubt that is why the report refers again and again to the "additional bureaucratic burdens that severity reporting would bring [to licensees]". Secondly, further consideration must be given as to whether severity can be satisfactorily categorised into three bands -the "moderate" category must cover a very wide spectrum from what is virtually "mild" to what is almost "substantial". That, combined with a suspicion that it may frequently be found convenient to classify as "moderate", something which really ought to be considered "substantial", throws doubt on the value of assessing severity, whether it is before a project is licensed, while it is taking place, or after it has been completed. These two concerns are linked, in that the WG recognised that there have been various suggestions that the "moderate" category should be divided into "upper moderate" and "lower moderate" categories. However, while they concluded that this "would improve the descriptive power of the classification system", they also felt that "increasing the number of severity categories would increase the burden of reporting".
Further attention should be given to the severity categories as a matter of urgency, since retrospective reporting will only be of any value, if what is reported has an acceptable and meaningful basis. It should also be remembered that, while common sense requires that costs to licensees and the establishments where they work must be taken into account, the principal duty of the Home Secretary is to weigh the balance between benefits (to us) and costs to the animals used in licensed procedures. Licensees should accept that the burdens imposed on them in the interests of animal welfare are the price they must pay for the privilege of using animals in their project work.
Proposal for the Reform of Directive 86/609/EEC
Just after the LASA/APC WG report became available, the European Commission published its longawaited Proposal for a Directive of the European Parliament and of the Council on the Protection of Animals Used for Scientific Purposes, 8 with the aim of replacing Directive 86/609/EEC regarding the protection of animals used for experimental and other scientific purposes. 9 The Commission's Proposal will also be discussed in detail in a future issue or issues of ATLA, so I will confine my comments to some of what it has to say about benefits, costs and retrospective assessment.
Severity is addressed in Article 15, which indicates classification into "up to mild", "moderate", "severe" or "non-recovery", and promises that the Commission "shall establish criteria for classification of procedures".
One of the positive developments in Great Britain since 1987 has been the introduction of an ethical review process in each licensed establishment. This is matched in Article 25 of the Proposal, which would require that EU Member States "shall ensure that each breeding, supplying and user establishment sets up a permanent ethical review body", which, inter alia, shall provide advice on matters "related to the welfare of animals in relation to their acquisition, accommodation, care and use", as well as on the application of the Three Rs, taking into account "the latest technical and scientific developments".
However, as in Great Britain, it is hard to see how ethical advice can be effectively provided, if the classification of effects on the animals used is based on the employment of an unsatisfactorily wide "virtually-mild to almost-severe" band for what is to be classed as "moderate". It is therefore to be hoped that the Commission will carefully consider this deficiency, when establishing the criteria for the classification of procedures.
In Article 37(2)(d), the Proposal spells out a requirement that the ethical evaluation shall consider "a harm-benefit analysis of the project, to assess whether the harm to the animals in terms of suffering, pain and distress, and to the environment, where appropriate, is justified by the expected advancement of science that ultimately benefits human beings, animals or the environment".
Article 38(1) refers to retrospective assessment, and indicates that "The ethical evaluation shall determine, on the basis of the harm-benefit analysis referred to in point (d) of Article 37(2), whether the project should, once it has been completed, be assessed retrospectively by the competent authority. If a retrospective assessment is deemed appropriate, the ethical evaluation shall determine, in relation to the project concerned, the deadline by which the retrospective assessment is to take place."
Article 38(3) indicates that "All projects using non-human primates shall undergo a retrospective assessment", while Article 38(4) says that all projects involving only procedures classified as 'up to mild' [other than those involving non-human primates] shall be exempted from the requirement for a retrospective assessment.
Clearly, as in the case of the classification of procedures according to severity, the Commission will need to issue clear guidance on how ethical review bodies should decide whether or not a project should undergo retrospective assessment.
The Weighing of Benefits and Costs
In the world of risk assessment, where risk = hazard × exposure, it is obvious (but not always recognised and applied) that an inadequate evaluation hazard or an inadequate estimation of exposure means that the risk assessment will be flawed. The truth that overall strength depends on all the links in a chain is no less true of the assessment and weighing of benefits and costs in relation to the performance of animal procedures -the quality and credibility, and even the legality, of the outcome will depend on the validity of the whole process.
Thus, although the assessment of benefits has been addressed in numerous reports, and was discussed in detail in the Report of the APC for 1997, 11 as well as in the subsequent APC report on the cost-benefit assessment, 4 it is widely felt to be a serious weaknesses in the current application of Clause 5(4) of the 1986 Act.
This especially applies to fundamental research, where scientists all-too-often seem to get away with the promise that some day, somehow, somewhere, their work will contribute to the solving of one or more of the grave problems of the day, such as cancer or dementia. This difficulty is recognised in the Home Office Guidance, 2 in the following words: "The likely benefit is primarily derived from the utility of the data or product to result from the programme of work, rather than the importance of the general area of study. Thus, although the longterm objective may be to find new medical treatments, the benefit for the purposes of the cost/benefit assessment relates to the progress likely to result directly from the programme outlined in the project licence application."
Another serious problem is the performance of tests to satisfy the regulatory requirements for chemicals, medicines, pesticides and other products. Here, the implication of the Guidance 2 is also clearly spelled out: "Applications for regulatory toxicity and safety testing are generally premised on the need to facilitate scientifically sound regulatory decisions for the protection of man and the environment, rather than on the utility or benefit of the end-product. The requirements of international regulators do not, in themselves, constitute sufficient benefit if alternative tests are available."
Nevertheless, in both cases, current practice does not appear to meet the standards so explicitly stated in the Guidance. Fundamental researchers seem to be able to apply their traditional procedures for decades without delivering any obvious breakthroughs or benefits, but any apparent restriction of their freedom to do so is met by cries of horror from the powerful lobby which promotes animal-based research. The need to redress this situation is raised in a letter from André Menarche in this issue of ATLA, 11 and is also the focus of SABRE Research UK, "an independent charity that represents the interests of patients and research volunteers by calling for rigorous scientific methods to assess the medical value of research involving animals", and which recently petitioned the Prime Minister "to improve the methods used to evaluate the validity and relevance of animal experiments. 12 The situation with regulatory testing is no more satisfactory, since the current application of animal testing is required by regulators, and therefore permitted by competent authorities such as the Home Office, despite its scientific weakness and its inability "to facilitate scientifically sound regulatory decisions. Let us consider, for example, the two kinds of testing which involve the greatest costs to industry and to animals. Can the two-species rodent bioassay be used to identify which chemicals are likely to cause cancer in humans? And can the current test guidelines for reproductive toxicity be used tell us which chemicals are likely to be embryotoxic or teratogenic in humans? The answer in both cases is No! It therefore follows that, if it cannot be scientifically established that the data produced by a test are relevant and reliable for any useful purpose, there can be no value in performing the test. And how can it be acceptable that its performance continues to be required by the regulators and permitted under the legislation intended to protect animals from unnecessary suffering? The urgent need for a revolution in toxicology, which surely should be matched by the ways in which laws are regulations are applied to animal testing, is discussed in this issue of ATLA by Thomas Hartung. 13 
